Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06968845 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
A Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), sponsored by Rein Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 5
- Study locations
NCT06968845: Recruiting Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), sponsored by Rein Therapeutics.
NCT06968845 is a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF) that is actively recruiting participants, run by Rein Therapeutics. The registered enrollment target is 120 participants, below the 482-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06968845, a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), is actively recruiting participants, sponsored by Rein Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 5
- Study locations
Study Summary
Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung disease caused by the death of lung cells involved in oxygen uptake and by progressive fibrosis (scarring) of the lungs. As the disease progresses, patients experience loss of lung function and increased breathing problems. LTI-03 is hypothesized to treat IPF by protecting and restoring the function of the oxygen uptake cells and by controlling lung fibrosis which may result in improving lung scarring. The purpose of this research is to evaluate LTI-03 including: its safety, whether it causes side effects, whether it improves lung scarring, and whether it improves IPF symptoms. LTI-03 will be compared to placebo in patients diagnosed with IPF within the last 5 years. Patients on a stable dose of nintedanib, pirfenidone, or nerandomilast (if available by prescription) may participate. Trial Design: This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center study that includes a 28-day Screening Period, a 24-week Treatment Period, and 4-week Follow-up Period. Study Assessments: Up to 9 visits to the study clinic will be required. Safety and tolerability will be evaluated with the following assessments: physical examination; collection of vital sign data (heart rate, blood pressure, respiratory rate and peripheral oxygen saturation \[SpO2\] via pulse oximetry); heart data collected by 12-lead electrocardiogram; and collection of blood samples for safety laboratory tests. In addition, participants will be asked about any adverse events (side effects) they have experienced between clinic visits, if they have changed any medications, and if they are able to properly use their study drug inhaler. Participants will undergo a lung function test (spirometry) at every visit, which will be used to evaluate both safety and efficacy. Another test measuring th
Conditions Studied
Interventions
- DRUG Placebo
- DEVICE Dry Powder Inhaler
- DRUG LTI-03
Study Locations (5)
Alabama
- UAB Lung Health Center - Birmingham
California
- Paradigm Clinical Research Centers, LLC - San Diego
Missouri
- The Lung Research Center, LLC - Chesterfield
South Carolina
- Medical University of South Carolina - Charleston
Texas
- El Paso Pulmonary Association - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06968845 shows while recruiting
NCT06968845 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 482-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis (IPF) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06968845 lists 5 locations in 5 states (Alabama, California, Missouri).
Frequently Asked Questions
What is clinical trial NCT06968845 about?
NCT06968845 is a clinical study titled "A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis". Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung disease caused by the death of lung cells involved in oxygen uptake and by progressive fibrosis (sc...
What is the current status of trial NCT06968845?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-02-02. Estimated completion is 2027-12-31.
What conditions does trial NCT06968845 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis (IPF).
What interventions are being tested in trial NCT06968845?
The interventions under investigation include: Placebo (DRUG), Dry Powder Inhaler (DEVICE), LTI-03 (DRUG).
Who is sponsoring clinical trial NCT06968845?
This trial is sponsored by Rein Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06968845 being conducted?
This trial has 5 study locations across Alabama, California, Missouri, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis (IPF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06968845's enrollment target sits among peer trials
120 5th of 8 higher than 4 of 8 other Idiopathic Pulmonary Fibrosis (IPF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis (IPF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RECRUITING · Phase 2
-
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
RECRUITING · Phase 2
-
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
COMPLETED · Phase 2
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
The Genetics of Pulmonary Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI